NorthWest Biotherapeutics Inc (NWBO)

[pqr]

Merck's Latest Deal Shows Pharma Interest in Oncology Assets -- Market Talk
Mentioned: IMGN IMGO MRK MRTX
14:01 ET - Merck's deal to buy blood-cancer biotech Imago BioSciences for $1.35B represents the third acquisition in the myeloproliferative neoplasm space in the last 18 months according to Guggenheim, and confirms continued appetite from pharma for targeted small-molecule assets with clinical data. Analysts say Merck has less presence in the MPN category than others who might have been a fit for Imago. "Overall, we think this deal bodes well for names with clinically de-risked, later stage oncology assets with clear paths to markets including ImmunoGen and Mirati Therapeutics," the analysts say. ImmunoGen gains 1.8% to $5.32 and Mirati falls 1.6% to $75.52. ([e-mail])